A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

NCT07493239 | Recruiting

• 1 other identifier: PS24
• Study Type: interventional
• Target: 240
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates the effect of two different doses of a consumer-grade product, MyCondro™, on individuals experiencing mobility issues related to knee osteoarthritis. The primary goal is to measure improvements in overall joint health and mobility by tracking changes in participants' total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores from the beginning to the end of the trial. Additionally, the study aims to assess secondary outcomes, including the product's impact on pain, stiffness, knee function, patient-reported improvement, inflammatory blood markers (CRP), and daily physical activity.

Conditions

Joint Health

Keywords

MyCondro, Gnosis, PS24; Joint function; Joint mobility; non-animal chondroitin sulfate

Outcome Measures

Primary Outcomes (1)

• MyCondro's effectiveness

  To evaluate the effectiveness of two different doses of MyCondro on mobility, activity, and joint health by measuring the change in total WOMAC scores from baseline to the end of the study within each dose group

  12 weeks

Secondary Outcomes (7)

• Knee Symptoms and Physical Function

  14 weeks

• Knee pain at rest and in motion

  14 Weeks

• Subjective Impression of Improvement

  14 weeks

• Overall Quality of Life

  14 weeks

• Systemic Inflammatory Blood Markers

  14 weeks

Other Outcomes (2)

• Physical Activity via wearable device

  14 weeks

• Participant Experience and Study Design Feedback

  14 weeks

Study Arms (2)

300 mg

EXPERIMENTAL

Participants in this arm will receive a 300 mg daily dose of the supplement, administered as two capsules every morning after breakfast for a 12-week period

Dietary Supplement: MyCondro 300mg

600 mg

EXPERIMENTAL

Participants in this arm will receive a 600 mg daily dose of the supplement, administered as two capsules every morning after breakfast for a 12-week period

Dietary Supplement: MyCondro 600mg

Interventions

MyCondro 300mg DIETARY_SUPPLEMENT

This is a non-animal Chondroitin sulfate formulation.

300 mg

MyCondro 600mg DIETARY_SUPPLEMENT

This is a non-animal Chondroitin sulfate formulation.

600 mg

Eligibility Criteria

• Age: 45 Years+
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Individuals age 45 years and older.
• BMI range between 18-35 kg/m².
• Self-reported mobility issues, including mobility impairment and joint discomfort associated with a known diagnosis of Knee Osteoarthritis. This impairment and discomfort must have persisted for at least 6 months prior to randomization and have been actively experienced within the last 3 months.
• Willingness to avoid high Chondroitin Sulfate-containing foods (i.e., animal cartilages, bones, or derivatives such as gelatin) for the duration of the study period.
• Willingness to refrain from supplements containing Chondroitin Sulfate for the duration of the study period.
• Able to read and understand English.
• Able to read, understand, and provide informed consent.
• Able to use a personal smartphone device and download the Chloe by People Science app.
• Able to receive shipments of the product at an address within the United States.
• Able to complete study assessments over the course of up to 16 weeks.

You may not qualify if:

• Any potential participants will be excluded if they meet any of the following criteria:
• Technology Limitation: Do not have a personal smartphone, lack internet access, or are unwilling to download the Chloe app.
• Concomitant Therapies
• Use of a Chondroitin Sulfate supplement in the 3 months prior to randomization.
• Current use of other joint health supplements (e.g., glucosamine, hyaluronic acid, collagen peptides) for at least 4 weeks prior to randomization.
• Use of any intra-articular or intravenous steroid injections in the last 3 months.
• Receiving any investigational therapies or treatments within 30 days prior to randomization.
• Other Illnesses or Conditions
• Self-reported inflammatory arthropathies, such as Rheumatoid Arthritis, Gout, and Infectious Arthritis.
• Significant systemic lung, liver, heart, or kidney disease (excluding hypertension).
• Prior history of knee surgery within 3 months preceding the study period, or planned knee surgery (including arthroscopy) during the study period.
• Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder.
• Currently pregnant, planning to become pregnant in the next 20 weeks, or breastfeeding.
• Presence of a knee prosthesis.
• Any significant illness, disease, or condition which, in the opinion of the Principal Investigator, may impact the ability to participate in the study or impact the study outcomes.

Sponsors & Collaborators

• Lesaffre International: lead
• People Science: collaborator

Study Sites (1)

People Science

Los Angeles, California, 90045, United States

RECRUITING

MeSH Terms

Conditions

Noonan syndrome 3

Study Officials

• Noah Craft, MD, PhD

  People Science

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Victoria Oyedokun, PhD

CONTACT

+4915163496903; v.oyedokun@gnosis.lesaffre.com

Yann Fardini, PhD

CONTACT

y.fardini@gnosis.lesaffre.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 19, 2026
• First Posted: March 25, 2026
• Study Start: March 4, 2026
• Primary Completion (Estimated): October 5, 2026
• Study Completion (Estimated): November 2, 2026
• Last Updated: July 22, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)